G.14.2.3 **Diabetes**

	Quality assessment						No of patients		Effect estimate	Quality
No of studies	Design	Risk of bias	Indirectness	Inconsistency	Imprecision	Other considerations	Pioglitazone (n=21)	No drug (n=21)	Summary of results	
Clinical progression of comorbidity & associated symptoms										
Mean difference in fasting plasma glucose at 6 months (Pioglitazone versus Control)										
Sato 2011	Randomised open controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD -0.50 (-1.14, 0.14)	Low
Mean difference in HBA1c at 6 months (Pioglitazone versus Control)										
Sato 2011	Randomised open controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD -0.10 (-0.68, 0.48)	Low
Mean difference in fasting insulin at 6 months (Pioglitazone versus Control)										
Sato 2011	Randomised open controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD -0.80 (-2.32, 0.72)	Low

Quality assessment							No of patients		Effect estimate	Quality
No of studies	Design	Risk of bias	Indirectness	Inconsistency	Imprecision	Other considerations	Pioglitazone (n=21)	No drug (n=21)	Summary of results	
Clinical outcomes, including cognitive, functional, behavioural ability										
Mean difference in MMSE at 6 months (Pioglitazone versus Control)										
Sato 2011	Randomised open controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD-1.50 (-0.67, 3.67)	Low
Mean difference in ADAS-Cog at 6 months (Pioglitazone versus Control)										
Richard 2012	Randomised controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD -3.30 (-6.86, 0.26)	Low
Mean difference in WMS-R logical memory at 6 months (Pioglitazone versus Control)										
Richard 2012	Randomised controlled trial	Not serious	Not serious	N/A	Very serious[1]	None	21	21	MD 2.40 (-0.13, 4.93)	Low

1. Downgrade 2 levels, non-significant effect and small sample size